Metastatic Melanoma Clinical Trials 2025: 75+ Pipeline Drugs, Targeted Therapies, and Immuno-Oncology Strategies Drive Progress

DelveInsight's "Metastatic Melanoma - Clinical Trials, 2025" reviews 75+ therapies currently in development for metastatic melanoma, one of the most aggressive forms of skin cancer with limited survival in advanced stages. Companies such as Evaxion Biotech, InxMed, AiVita Biomedical, and Iovance Biotherapeutics are driving innovation beyond standard immune checkpoint inhibitors and BRAF/MEK-targeted therapies.

The clinical trial landscape is expanding with next-generation immunotherapies, including bispecific antibodies, adoptive T-cell therapies, oncolytic viruses, and novel checkpoint inhibitors. Targeted agents for NRAS, c-KIT, and other resistant subtypes, as well as combination regimens pairing immunotherapy with small molecules, are under active evaluation to address treatment resistance.

With multiple Phase II and Phase III trials underway, the focus is shifting toward precision-driven and immune-based strategies. As these late-stage candidates advance, the metastatic melanoma treatment landscape is expected to transform, offering more durable responses and improved survival outcomes for patients.

Interested in learning more about the current treatment landscape and the key drivers shaping the metastatic melanoma pipeline? Click here: https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Metastatic Melanoma Pipeline Report
• DelveInsight's metastatic melanoma pipeline analysis depicts a strong space with 75+ active players working to develop 75+ pipeline drugs for metastatic melanoma treatment.
• The leading metastatic melanoma companies include Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others are evaluating their lead assets to improve the metastatic melanoma treatment landscape.
• Key metastatic melanoma pipeline therapies in various stages of development include EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, and others.
• In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.
• In July 2025, the FDA issued a Complete Response Letter for Replimune Group's Biologics License Application for RP1 combined with nivolumab, targeting advanced melanoma. The FDA cited concerns about the IGNYTE trial's design and patient population heterogeneity, stating it did not provide sufficient evidence of effectiveness. No safety issues were noted.
• In February 2025, Bristol Myers Squibb announced that the phase III RELATIVITY-098 trial of Opdualag (nivolumab and relatlimab-rmbw) for adjuvant treatment of completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). The safety profile of Opdualag was consistent with the known profiles of nivolumab and relatlimab.
• In January 2025, the FDA accepted the biologics license application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab (OPDIVO) as a treatment for patients with advanced melanoma.

Request a sample and discover the recent breakthroughs happening in the metastatic melanoma pipeline landscape at https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Melanoma Overview
Metastatic melanoma is an advanced stage of skin cancer where malignant melanoma cells have spread from the original tumor site to other parts of the body, such as lymph nodes, lungs, liver, brain, or bones. This aggressive form of melanoma is challenging to treat due to its ability to invade distant tissues and resist conventional therapies. Symptoms can vary widely depending on the organs involved but may include new or enlarging skin lesions, unexplained weight loss, fatigue, and organ-specific issues. Early diagnosis and advanced treatments like targeted therapy, immunotherapy, and sometimes chemotherapy have improved outcomes, but metastatic melanoma remains a serious condition requiring specialized medical care and ongoing research for better therapies.

Find out more about metastatic melanoma medication at https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Melanoma Treatment Analysis: Drug Profile
EVX-01: Evaxion Biotech
EVX-01 is an innovative personalized cancer immunotherapy developed using Evaxion's proprietary PIONEERTM AI technology. It has demonstrated a favorable safety profile and promising early signs of clinically meaningful antitumor activity. Clinical data indicate that EVX-01 can stimulate T-cell responses when administered alongside standard immune checkpoint inhibitors, such as anti-PD-1 therapy. Studies have shown that EVX-01, in combination with anti-PD-1 treatment, produces an enhanced antitumor effect. The drug is currently in Phase II clinical trials for the treatment of metastatic melanoma.

IN 10018: InxMed
IN10018 is a highly potent and selective ATP-competitive inhibitor of focal adhesion kinase (FAK), with InxMed holding exclusive global development and commercialization rights. Early clinical results have demonstrated its safety and efficacy across multiple tumor types. Recent preclinical and clinical findings suggest that IN10018 may be effective in combination therapies by overcoming tumor-associated fibrosis and enhancing local immune responses. This positions IN10018 as a promising anchor molecule for synergistic use with immunotherapy, chemotherapy, and targeted treatments. Currently, IN10018 is undergoing Phase I clinical evaluation for metastatic melanoma.

Learn more about the novel and emerging metastatic melanoma pipeline therapies at https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Melanoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Metastatic Melanoma Pipeline Report
• Coverage: Global
• Key Metastatic Melanoma Companies: Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
• Key Metastatic Melanoma Pipeline Therapies: EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, and others.

To dive deep into rich insights for drugs used for metastatic melanoma treatment, visit: https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Melanoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Melanoma Pipeline Therapeutics
6. Metastatic Melanoma Pipeline: Late-Stage Products (Phase III)
7. Metastatic Melanoma Pipeline: Mid-Stage Products (Phase II)
8. Metastatic Melanoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.